Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-21447 in Mature B-Cell Malignancies
NCT05828589Phase 1Terminated
- Sponsor
- BeOne Medicines
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of bgb-21447 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 4 more (4 cohorts), sponsored by BeOne Medicines. Primary endpoints: Dose Limiting Toxicities at 1 month, Adverse Events at 12 months and 1 more. Started Jun 2023; status: terminated.
02
Drugs
bgb-21447
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05828589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828589.